Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 182 | 0.85 |
| pathways Reactome | 14 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4377
Sealed predictions
- PAFAH1B1 in dopamine neurons, braak-0.05 (p 0.907) → +0.53 (p 0.140)receipt 4384
Swarm cases
receipt 4384: PAFAH1B1 in dopamine neurons, braak
- power
- full sample +0.09 (p 0.735, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.161, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.19, sign flips 3; without severely affected donors +0.09 (p 0.735, n 18). fragile.
- cell type
- strongest in microglia: -0.62 (p 0.0064, n 18) vs +0.09 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PAFAH1B1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PAFAH1B1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 4.5e-4)
Receipts
loading the receipts